-
Certolizumab pegol, sold
under the
brand name
Cimzia, is a
biopharmaceutical medication for the
treatment of Crohn's disease,
rheumatoid arthritis, psoriatic...
- followed,
including Keppra (levetiracetam),
Xyzal (levocetirizine), and
Cimzia (certolizumab pegol),
which arrived through the
acquisition of Celltech...
- 30, 2020. Ot****
Pharmaceutical Co., Ltd. and UCB
Group (UCBJF.PK) End
Cimzia Collaboration, to
Focus on CNS
Disorders Instead, BioSpace,
January 13,...
- CDP870 was UCB's
company code for
certolizumab pegol; UCB
later chose "
Cimzia" as its
trade name. Many of
these codes,
although not all, have prefixes...
- doi:10.17305/bjbms.2018.2792. PMC 6087553. PMID 29338679. "FDA
Approves Cimzia to
Treat Crohn's Disease" (Press release). Food and Drug Administration...
-
carcinoma Cergutuzumab amunaleukin mab
humanized IL-2
cancer Certolizumab pegol Cimzia Fab'
humanized TNF-α Y Crohn's disease,
rheumatoid arthritis,
axial spondyloarthritis...
- (Remicade)
binding directly to TNF,
adalimumab (Humira),
certolizumab pegol (
Cimzia) or with a
decoy circulating receptor fusion protein such as etanercept...
- "Tumor
Necrosis Factor (TNF)
Blockers (marketed as Remicade, Enbrel, Humira,
Cimzia, and Simponi)
August 2009". U.S. Food and Drug
Administration (FDA). 31...
-
diagnosed prostate cancer or post-prostatectomy 103608 Link
certolizumab pegol Cimzia UCB (company) 4/22/2008
subcutaneous humanized TNF Crohn's
disease 125160...
-
PEGylated uricase for the
treatment of gout (Savient, 2010)
Certolizumab pegol (
Cimzia) –
monoclonal antibody for
treatment of
moderate to
severe rheumatoid arthritis...
